Novavax’s coronavirus vaccines delivered to Finland – the product is primarily used for the first and second vaccine doses
Novavax's protein-based vaccine Nuvaxovid arrived in Finland last week. The vaccine provides protection against an infection and disease caused by the coronavirus.
The vaccine has a marketing authorisation in the European Union for the first and second vaccine doses of those aged 18 or over. The European Medicines Agency (EMA) granted a conditional marketing authorisation for the vaccine product on 20 December 2021.
The Nuvaxovid vaccine is primarily recommended for persons who cannot be administered the previously introduced mRNA or adenoviral vector vaccines. The vaccine may also be administered to other persons aged 18 or over who want a protein-based vaccine instead of other vaccine products.
“It should be noted, however, that initially there may not be enough vaccines for everyone who wants them. Unvaccinated persons over the age of 60 and those in medical high-risk groups who have refused other vaccines have the greatest medical need to get this vaccine if they so wish,” says Mia Kontio, Chief Specialist at THL.
Number of received vaccine products is limited
The Nuvaxovid vaccine is suitable for almost all adults. For example, having previously had coronavirus disease is not a contraindication for vaccination.
The Nuvaxovid vaccine does not have a marketing authorisation for the third vaccine doses. For the time being, the vaccine product is not administered as a third dose, except in exceptional cases when the mRNA or adenoviral vector vaccines cannot be administered for medical reasons.
During March, approximately 235,000 vaccine doses will be delivered to Finland. More will be available between April and June, but a more detailed timetable is still open.
“The vaccines may not be available in all coronavirus vaccination points, but municipalities will inform where the Nuvaxovid vaccine can be received,” Kontio explains.
Further information:
Frequently asked questions about Novavax's protein-based vaccine
Mia Kontio
Chief Specialist
THL
[email protected]
Hanna Nohynek
Chief Physician
THL
[email protected]
